Table 1. Sample demographics and logistic regression testing the relationship between demographics, comorbidities, cancer stage, and receiving a CEA, endoscopy, and CT scan within NCCN surveillance guidelines (n=205).

		Univariate		Multivariate
	N (%)	OR	95% CI	OR	95% CI
Age (mean, SD)	56.1 (11)	0.98	0.96, 1.01	0.97	0.94, 1.00
Gender
Female	94 (46)	-	-	-	-
Male	111 (54)	0.82	0.46, 1.44	0.62	0.33, 1.19
Race/Ethnicity
White Non-Hispanic	41 (20)	-	-	-	-
Black Non-Hispanic	78 (38)	2.34*	1.03, 5.32	2.38	0.96, 5.87
Hispanic	77 (38)	1.74	0.76, 3.99	2.40	0.92, 6.28
Other	9 (4)	0.34	0.04, 3.05	0.51	0.05, 5.24
Health Insurance
Private/Commercial	12 (6)	-	-	-	-
Medicare	68 (33)	0.59	0.06, 5.47	0.79	0.07, 9.20
Medicaid	5 (2)	1.85	0.97, 3.53	2.76*	1.20, 6.31
Uninsured	97 (47)	2.74	0.85, 8.84	2.17	0.60, 7.76
Other	22 (11)	2.34	0.91, 6.01	2.25	0.73, 6.92
Number of Comorbidities
0	21 (10)	-	-	-	-
1	36 (18)	1.27	0.41, 3.93	0.99	0.29, 3.40
2	38 (19)	0.71	0.22, 2.28	0.85	0.24, 3.09
3+	110 (54)	1.49	0.56, 3.99	1.37	0.41, 4.53
Physical exam (6 months)	21 (10)	0.35	0.11, 1.08	1.37	0.71, 2.67
Cancer stage
I	38 (19)	0.43*	0.19, 0.96	0.35*	0.14, 0.87
II	72 (36)	0.43*	0.22, 0.82	0.36**	0.18, 0.74
III	92 (46)	-	-	-	-
Recommended surveillance modalities
Carcinoembryonic antigen levels (CEA)a	156 (76)
Endoscopyc	104 (51)
CEAa + Endoscopyc	89 (43)
CEAa + Endoscopyc + CT scanb	78 (38)
Computed tomography (CT)	146 (71)
scana
CT scanb	164 (80)
Physical examb	36 (18)

^a-6 months,

^b-12 months,

^c-15 months

^*p-value < 0.05;

^**p-value < 0.01